Definitive Contract 75N91022C00057
Award Date 9/16/22
Potential Completion Date 9/15/24
Potential Value $390K
Federal Agency
Ultimate Awardee
Not listed Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
College Station, TX, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
12
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed Similar Awards
- This is a $382,034 Small Business Innovation Research (SBIR) Phase I contract awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to Phoenix Biosystem, Inc., a self-certified small disadvantaged business. The contract is for the development of HPV point-of-care molecular diagnostics for low- and middle-income countries. The original pre-solicitation announced that NIH and CDC were seeking SBIR proposals to advance their infectious...
- This $400,000 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Amplifidx Inc., a woman-owned small business. The contract supports the development of cancer prevention and diagnosis technologies for low-resource settings over a two-year period. This award aligns with NCI's mission to support innovative medical device research and development by small businesses. As a SBIR...
- This federal contract award, with an ID of 75N91021P00756, was issued by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH) under the Department of Health and Human Services (HHS). The $95,995 firm-fixed-price purchase order was awarded to Atila Biosystems Incorporated, a small business, to provide HPV genotyping assays and testing supplies to support the NCI's Division of Cancer Epidemiology and Genetics (DCEG) research efforts. The contract was...
- This Small Business Innovation Research (SBIR) Phase I contract, valued at $399,674, was awarded by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to Inso Biosciences Inc., a small biotechnology startup. The contract supports the research and development of advanced sample processing platforms for downstream single-cell multi-omic analysis. This work aligns with the NIH and Centers for Disease Control and Prevention (CDC) mission to develop medical...
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), which is part of the National Institutes of Health (NIH), to Pathovacs Inc., a small biotechnology company based in Ames, Iowa. The $393,833 firm-fixed-price contract supports the development of a prototype in vitro diagnostic device for qualitative screening of individuals for anti-hepatitis C virus (HCV) antibodies to determine HCV exposure. This aligns with the NCI's mission to...
- <p>The National Cancer Institute (NCI) awarded a $198,141 Firm Fixed Price (FFP) contract to Aura Biosciences, Inc., a small business, to research the treatment of Human Papillomavirus (HPV)-positive head and neck cancer using small interfering RNA (siRNA) nanosphere particles. The contract has a completion date of September 24, 2014. This award appears to be a standalone contract and not part of a larger vehicle.</p>
- This federal contract award for $389,535 was made to Electronic Biosciences, Inc., a small business biotechnology company, by the National Cancer Institute (NCI) under the Small Business Innovation Research (SBIR) program. The contract is for the development of an "IDEAL AT-HOME PROSTATE SPECIFIC ANTIGEN (PSA) TESTING" solution, which aligns with NCI's mission to support innovative technologies for cancer diagnostics and prevention. The contract is a Firm Fixed Price, Definitive...
- This definitive contract award of $13,720 by the Department of Health and Human Services National Institutes of Health National Cancer Institute to Zymeron Corporation is for the research and development of a rapid point-of-care test to screen for human papillomavirus in low-resource settings. The contract is associated with Solicitation PHS-2023-1 of the NIH and Centers for Disease Control and Prevention Small Business Innovation Research Program Phase I, which sought proposals to address...
- This is a $454,183 firm fixed-price contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Inbios International Inc., a minority-owned, for-profit biotechnology company based in Seattle, Washington. The contract, which is set aside for small businesses, is for the development of a rapid at-home test to detect prostate-specific antigen using self-collected finger stick blood. This contract was awarded under the NCI's Small Business...
- This is a $300,000.00 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institutes of Health (NIH) National Cancer Institute to Base Pair Biotechnologies Inc., a for-profit company that provides custom aptamer development services and products to the federal government. The contract is for the "Development and Validation of Non-Mouse Reagents to Enable Preclinical Development of Novel Therapeutics", which was one of the research topics identified in the...